| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8647514 | Multiple Sclerosis and Related Disorders | 2018 | 14 Pages |
Abstract
This is a first report of ketonuria in a MS-patient with T1D treated with DMF. Patients with MS and co-existing metabolic diseases, which are not contraindicated for DMF treatment, represent a unique opportunity to address questions regarding the possible mechanisms of action of DMF on the cellular metabolism. The use of DMF in patients with metabolic diseases needs closer attention.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Ewa Krzystanek, Przemyslawa Jarosz-Chobot,